纳武利尤单抗联合低剂量伊匹木单抗一线治疗MSI-H/dMMR转移性结直肠癌:II期CheckMate 142研究
该II期研究评估纳武利尤单抗联合低剂量伊匹木单抗一线治疗MSI-H/dMMR转移性结直肠癌,共45例患者,中位随访29.0个月。客观缓解率69%,疾病控制率84%,完全缓解率13%,中位缓解持续时间、无进展生存和总生存均未达到,24个月无进展生存率和总生存率分别为74%和79%。3-4级治疗相关不良事件发生率22%。
要点
- 一线纳武利尤单抗联合低剂量伊匹木单抗在MSI-H/dMMR转移性结直肠癌中客观缓解率达69%。
- 中位随访29.0个月时中位无进展生存和总生存均未达到,24个月率分别为74%和79%。
- 3-4级治疗相关不良事件发生率22%,13%因任何级别治疗相关不良事件停药。
核心结论
- 纳武利尤单抗联合低剂量伊匹木单抗一线治疗MSI-H/dMMR转移性结直肠癌显示出稳健且持久的临床获益,耐受性良好。
研究设计与样本
- II期CheckMate 142研究的一线治疗队列,纳入45例未接受过转移性疾病治疗的MSI-H/dMMR结直肠癌患者。
- 治疗方案为纳武利尤单抗每2周联合低剂量伊匹木单抗每6周,直至疾病进展。
- 主要终点为研究者评估的客观缓解率(RECIST v1.1)。
主要发现
- 中位年龄66岁,中位随访29.0个月。
- 客观缓解率为69%(95% CI,53至82),疾病控制率为84%(95% CI,70.5至93.5),完全缓解率为13%。
- 中位缓解持续时间未达到,74%的缓解者在数据截止时仍有持续缓解。
- 中位无进展生存和总生存均未达到,最短随访24.2个月,24个月无进展生存率和总生存率分别为74%和79%。
- 无论基线人口学和肿瘤特征(包括BRAF或KRAS突变状态)均观察到临床获益。
关键数值与推荐
- 客观缓解率69%(95% CI,53至82),疾病控制率84%(95% CI,70.5至93.5),完全缓解率13%。
- 24个月无进展生存率74%,24个月总生存率79%。
- 3-4级治疗相关不良事件发生率22%,13%因任何级别治疗相关不良事件停药。
临床怎么用
- 对于未接受过治疗的MSI-H/dMMR转移性结直肠癌患者,可考虑纳武利尤单抗联合低剂量伊匹木单抗作为一线治疗选择。
- 治疗期间患者报告结局保持稳定,支持该方案在临床实践中的耐受性。
局限性
- 本研究为单臂II期研究,样本量有限(N=45),无随机对照。
- 中位无进展生存和总生存未达到,长期生存获益需更长时间随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.
引用
- Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2021. PMID: 34637336. doi:10.1200/JCO.21.01015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。